Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurological disorders
Biotech
Merck KGaA becomes latest partner for Flagship’s Valo Health
Merck and Valo will use the latter’s discovery platform to quickly craft preclinical candidates for newly identified Parkinson's disease targets.
Darren Incorvaia
Nov 20, 2025 6:30am
Big Pharma-backed MapLight plots IPO
Sep 22, 2025 1:57pm
Ionis rare disease candidate ekes out phase 3 win
Sep 22, 2025 10:46am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
Merck KGaA swoops to $2B neurological disease pact with Skyhawk
Aug 18, 2025 9:49am
Arialys presents promising data for IgG1 antibody treatment
Jun 20, 2025 5:02am
